Anti-interleukin-6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagen-induced arthritis model

Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study

(2012) Stephanie Finzel et al.   ANNALS OF THE RHEUMATIC DISEASES

Higher Circulating Sphingosine 1-Phosphate Levels Are Associated with Lower Bone Mineral Density and Higher Bone Resorption Marker in Humans

(2012) Seung Hun Lee et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

LPS and TNF-α induce expression of sphingosine-1-phosphate receptor-2 in human microvascular endothelial cells

(2012) Jing Du et al.   PATHOLOGY RESEARCH AND PRACTICE

IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522)

(2012) Morten A. Karsdal et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Effect of Raloxifene on Arthritis and Bone Mineral Density in Rats with Collagen-Induced Arthritis

(2010) Ikuta Hayashi et al.   CALCIFIED TISSUE INTERNATIONAL

Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

(2010) Shigeru Kotake et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo

(2010) Masaru Ishii et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CXC Chemokine Ligand 2 Induced by Receptor Activator of NF- B Ligand Enhances Osteoclastogenesis

(2010) J. Ha et al.   JOURNAL OF IMMUNOLOGY

IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis

(2010) Hiroto Yoshida et al.   RHEUMATOLOGY INTERNATIONAL

Rapid and sustained improvement in bone and cartilage turnover markers with the anti–interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone

(2009) Patrick Garnero et al.   ARTHRITIS AND RHEUMATISM

Role of CX3CL1/Fractalkine in Osteoclast Differentiation and Bone Resorption

(2009) K. Koizumi et al.   JOURNAL OF IMMUNOLOGY

Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis

(2009) Masaru Ishii et al.   NATURE

Estrogen-dependent and C-C chemokine receptor-2–dependent pathways determine osteoclast behavior in osteoporosis

(2009) Nikolaus B Binder et al.   NATURE MEDICINE

Osteoimmunology and the effects of the immune system on bone

(2009) Hiroshi Takayanagi   Nature Reviews Rheumatology

A combination of methotrexate and zoledronic acid prevents bone erosions and systemic bone mass loss in collagen induced arthritis

(2009) Benoit Le Goff et al.   ARTHRITIS RESEARCH & THERAPY

Reciprocal cross-talk between RANKL and interferon-γ–inducible protein 10 is responsible for bone-erosive experimental arthritis

(2008) Han Bok Kwak et al.   ARTHRITIS AND RHEUMATISM